Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables - Net (2022 - 2025)

Amylyx Pharmaceuticals has reported Receivables - Net over the past 4 years, most recently at $88000.0 for Q4 2025.

  • Quarterly results put Receivables - Net at $88000.0 for Q4 2025, down 80.31% from a year ago — trailing twelve months through Dec 2025 was $88000.0 (down 80.31% YoY), and the annual figure for FY2025 was $88000.0, down 80.31%.
  • Receivables - Net for Q4 2025 was $88000.0 at Amylyx Pharmaceuticals, down from $132000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for AMLX hit a ceiling of $40.0 million in Q4 2023 and a floor of $88000.0 in Q4 2025.
  • Median Receivables - Net over the past 4 years was $2.9 million (2024), compared with a mean of $11.7 million.
  • Biggest five-year swings in Receivables - Net: surged 21325.55% in 2023 and later crashed 98.88% in 2024.
  • Amylyx Pharmaceuticals' Receivables - Net stood at $15.3 million in 2022, then soared by 161.66% to $40.0 million in 2023, then crashed by 98.88% to $447000.0 in 2024, then crashed by 80.31% to $88000.0 in 2025.
  • The last three reported values for Receivables - Net were $88000.0 (Q4 2025), $132000.0 (Q3 2025), and $103000.0 (Q2 2025) per Business Quant data.